Market & RegulationInvestment · $2.1B
DeepMind Spinout Isomorphic Labs Raises $2.1B
Siftedhigh confidence
Why it matters
- →Isomorphic Labs is leveraging AI to transform drug discovery, a field traditionally reliant on slower methods.
- →The $2.1 billion funding round indicates strong investor confidence in AI's potential to revolutionize pharmaceuticals.
- →Partnerships with major pharmaceutical companies suggest significant industry interest and potential for impactful collaborations.
Isomorphic Labs, a spinout from DeepMind, has raised $2.1 billion in a Series B funding round led by Thrive Capital. The round also saw participation from the UK’s Sovereign AI fund, Abu Dhabi’s MGX, Alphabet's GV, and Singapore’s Temasek. Founded in 2021, Isomorphic Labs is developing a drug discovery platform using AlphaFold technology to predict protein structures. The company has already partnered with pharmaceutical giants like Eli Lilly and Novartis and is advancing towards pre-clinical trials. This funding highlights the increasing role of AI in transforming drug discovery processes.
Read original
